c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-X_L

REFERENCES

• Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538.
   PubMed Web of Science ®Google Scholar
• Askew, D. S., R. A. Ashmun, B. C. Simmons, and J. L. Cleveland. 1991. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915–1922.
   PubMed Web of Science ®Google Scholar
• Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674–1677.
   PubMed Web of Science ®Google Scholar
• Baudino, T. A., and J. L. Cleveland. 2001. The Max network gone mad. Mol. Cell. Biol. 21: 691–702.
   PubMedGoogle Scholar
• Baudino, T. A., C. McKay, H. Pendeville-Samain, J. A. Nilsson, K. H. Maclean, E. L. White, A. C. Davis, J. N. Ihle, and J. L. Cleveland. 2002. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16: 2530–2543.
   PubMed Web of Science ®Google Scholar
• Bello-Fernandez, C., G. Packham, and J. L. Cleveland. 1993. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA 90: 7804–7808.
   PubMed Web of Science ®Google Scholar
• Bouillet, P., and A. Strasser. 2002. Bax and Bak: back-bone of T cell death. Nat. Immunol. 3: 893–894.
   PubMedGoogle Scholar
• Bouillet, P., and A. Strasser. 2002. BH3-only proteins—evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J. Cell Sci. 115: 1567–1574.
   PubMed Web of Science ®Google Scholar
• Boxer, L. M., and C. V. Dang. 2001. Translocations involving c-myc and c-myc function. Oncogene 20: 5595–5610.
   PubMed Web of Science ®Google Scholar
• Canman, C. E., D. S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677–1679.
   PubMed Web of Science ®Google Scholar
• Cavalieri, F., and M. Goldfarb. 1987. Growth factor-deprived BALB/c 3T3 murine fibroblasts can enter the S phase after induction of c-myc gene expression. Mol. Cell. Biol. 7: 3554–3560.
   PubMed Web of Science ®Google Scholar
• Chen, C. R., Y. Kang, P. M. Siegel, and J. Massague. 2002. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 110: 19–32.
   PubMed Web of Science ®Google Scholar
• Coller, H. A., C. Grandori, P. Tamayo, T. Colbert, E. S. Lander, R. N. Eisenman, and T. R. Golub. 2000. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 97: 3260–3265.
   PubMed Web of Science ®Google Scholar
• de Alboran, I. M., R. C. O'Hagan, F. Gartner, B. Malynn, L. Davidson, R. Rickert, K. Rajewsky, R. A. DePinho, and F. W. Alt. 2001. Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14: 45–55.
   PubMed Web of Science ®Google Scholar
• Deverman, B. E., B. L. Cook, S. R. Manson, R. A. Niederhoff, E. M. Langer, I. Rosova, L. A. Kulans, X. Fu, J. S. Weinberg, J. W. Heinecke, K. A. Roth, and S. J. Weintraub. 2002. Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell 111: 51–62.
   PubMedGoogle Scholar
• Eilers, M., S. Schirm, and J. M. Bishop. 1991. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 10: 133–141.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., G. Packham, J. Nip, B. E. Fee, S. W. Hiebert, G. P. Zambetti, and J. L. Cleveland. 2001. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 20: 6983–6993.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., M. F. Roussel, S. J. Korsmeyer, and J. L. Cleveland. 2001. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21: 7653–7662.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13: 2658–2669.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., D. Woo, M. F. Roussel, and J. L. Cleveland. 2001. Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 21: 5063–5070.
   PubMed Web of Science ®Google Scholar
• Evan, G. I., A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, and D. C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128.
   PubMed Web of Science ®Google Scholar
• Fei, P., E. J. Bernhard, and W. S. El-Deiry. 2002. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62: 7316–7327.
   PubMed Web of Science ®Google Scholar
• Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12: 2658–2663.
   PubMed Web of Science ®Google Scholar
• Harrington, E. A., M. R. Bennett, A. Fanidi, and G. I. Evan. 1994. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13: 3286–3295.
   PubMed Web of Science ®Google Scholar
• Hecht, J. L., and J. C. Aster. 2000. Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. 18: 3707–3721.
   PubMed Web of Science ®Google Scholar
• Heikkila, R., G. Schwab, E. Wickstrom, S. L. Loke, D. H. Pluznik, R. Watt, and L. M. Neckers. 1987. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328: 445–449.
   PubMed Web of Science ®Google Scholar
• Iritani, B. M., and R. N. Eisenman. 1999. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA 96: 13180–13185.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., A. A. Ruefli, and S. W. Lowe. 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153–164.
   PubMed Web of Science ®Google Scholar
• Juin, P., A. O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13: 1367–1381.
   PubMed Web of Science ®Google Scholar
• Juin, P., A. Hunt, T. Littlewood, B. Griffiths, L. B. Swigart, S. Korsmeyer, and G. Evan. 2002. c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell. Biol. 22: 6158–6169.
   PubMedGoogle Scholar
• Klocke, B. J., C. B. Latham, C. D'Sa, and K. A. Roth. 2002. p53 deficiency fails to prevent increased programmed cell death in the Bcl-XL-deficient nervous system. Cell Death Differ. 9: 1063–1068.
   PubMedGoogle Scholar
• Lemay, M., and K. A. Wood. 1999. Detection of DNA damage and identification of UV-induced photoproducts using the CometAssay kit. BioTechniques 27: 846–851.
   PubMed Web of Science ®Google Scholar
• Li, L. H., C. Nerlov, G. Prendergast, D. MacGregor, and E. B. Ziff. 1994. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J. 13: 4070–4079.
   PubMedGoogle Scholar
• Littlewood, T. D., D. C. Hancock, P. S. Danielian, M. G. Parker, and G. I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23: 1686–1690.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847–849.
   PubMed Web of Science ®Google Scholar
• Maclean, K., H. Yang, and J. L. Cleveland. 2001. Serum suppresses myeloid progenitor apoptosis by regulating iron homeostasis. J. Cell. Biochem. 82: 171–186.
   PubMedGoogle Scholar
• Mai, S., M. Fluri, D. Siwarski, and K. Huppi. 1996. Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res. 4: 365–371.
   PubMed Web of Science ®Google Scholar
• Marx, J. C., J. A. Allay, D. A. Persons, S. A. Nooner, P. W. Hargrove, P. F. Kelly, E. F. Vanin, and E. M. Horwitz. 1999. High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum. Gene Ther. 10: 1163–1173.
   PubMed Web of Science ®Google Scholar
• Maya, R., M. Balass, S. T. Kim, D. Shkedy, J. F. Leal, O. Shifman, M. Moas, T. Buschmann, Z. Ronai, Y. Shiloh, M. B. Kastan, E. Katzir, and M. Oren. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15: 1067–1077.
   PubMed Web of Science ®Google Scholar
• Mikhailov, V., M. Mikhailova, K. Degenhardt, M. A. Venkatachalam, E. White, and P. Saikumar. 2002. Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J. Biol. Chem. 278: 5367–5376.
   PubMedGoogle Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245.
   PubMed Web of Science ®Google Scholar
• Motoyama, N., F. Wang, K. A. Roth, H. Sawa, K. Nakayama, I. Negishi, S. Senju, Q. Zhang, S. Fujii, et al. 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506–1510.
   PubMed Web of Science ®Google Scholar
• Nakano, K., and K. H. Vousden. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7: 683–694.
   PubMed Web of Science ®Google Scholar
• Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053–1058.
   PubMed Web of Science ®Google Scholar
• Packham, G., E. L. White, C. M. Eischen, H. Yang, E. Parganas, J. N. Ihle, D. A. Grillot, G. P. Zambetti, G. Nunez, and J. L. Cleveland. 1998. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev. 12: 2475–2487.
   PubMedGoogle Scholar
• Pelengaris, S., M. Khan, and G. Evan. 2002. c-myc: more than just a matter of life and death. Nat. Rev. Cancer 2: 764–776.
   PubMed Web of Science ®Google Scholar
• Pelengaris, S., M. Khan, and G. I. Evan. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321–334.
   PubMed Web of Science ®Google Scholar
• Pelengaris, S., T. Littlewood, M. Khan, G. Elia, and G. Evan. 1999. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3: 565–577.
   PubMed Web of Science ®Google Scholar
• Pestina, T. I., J. L. Cleveland, C. Yang, G. P. Zambetti, and C. W. Jackson. 2001. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood 98: 2084–2090.
   PubMedGoogle Scholar
• Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
   PubMed Web of Science ®Google Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554–564.
   PubMed Web of Science ®Google Scholar
• Rupnow, B. A., A. D. Murtha, R. M. Alarcon, A. J. Giaccia, and S. J. Knox. 1998. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 58: 1779–1784.
   PubMed Web of Science ®Google Scholar
• Schmitt, C. A., J. S. Fridman, M. Yang, S. Lee, E. Baranov, R. M. Hoffman, and S. W. Lowe. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335–346.
   PubMed Web of Science ®Google Scholar
• Schmitt, C. A., M. E. McCurrach, E. de Stanchina, R. R. Wallace-Brodeur, and S. W. Lowe. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13: 2670–2677.
   PubMed Web of Science ®Google Scholar
• Schuler, M., and D. R. Green. 2001. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans. 29: 684–688.
   PubMed Web of Science ®Google Scholar
• Seoane, J., H. V. Le, and J. Massague. 2002. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729–734.
   PubMed Web of Science ®Google Scholar
• Sheen, J. H., and R. B. Dickson. 2002. Overexpression of c-Myc alters G1/S arrest following ionizing radiation. Mol. Cell. Biol. 22: 1819–1833.
   PubMedGoogle Scholar
• Sherr, C. J., and R. A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102: 407–410.
   PubMed Web of Science ®Google Scholar
• Sjostrom, J., C. Blomqvist, K. von Boguslawski, N. O. Bengtsson, I. Mjaaland, P. Malmstrom, B. Ostenstadt, E. Wist, V. Valvere, S. Takayama, J. C. Reed, and E. Saksela. 2002. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8: 811–816.
   PubMed Web of Science ®Google Scholar
• Tao, W., and A. J. Levine. 1999. p19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 96: 6937–6941.
   PubMed Web of Science ®Google Scholar
• Vafa, O., M. Wade, S. Kern, M. Beeche, T. K. Pandita, G. M. Hampton, and G. M. Wahl. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9: 1031–1044.
   PubMed Web of Science ®Google Scholar
• Vilenchik, M., A. J. Raffo, L. Benimetskaya, D. Shames, and C. A. Stein. 2002. Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res. 62: 2175–2183.
   PubMedGoogle Scholar
• Vousden, K. H., and X. Lu. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2: 594–604.
   PubMed Web of Science ®Google Scholar
• Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1: 20–26.
   PubMed Web of Science ®Google Scholar
• Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7: 673–682.
   PubMed Web of Science ®Google Scholar
• Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424–2433.
   PubMed Web of Science ®Google Scholar